Mark McDade
SlowingNamed in filings at Qiming U.S HealthcareOn the current fund
- Board seats filed
- 11
- Named on a board
- 1
all filings on record
Named in filings at Qiming U.S HealthcareOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Dualitas Therapeutics | Biotech & pharma | July 2025 | SV Life Sciences |
| Soda Health | Digital health | April 2024 | None on file |
| Boulder Care | Healthcare services | May 2022 | First Round Capital |
| WindMIL Therapeutics | Biotech & pharma | January 2021 | Domain Partners |
| Talaris Therapeutics | Biotech & pharma | September 2020 | Blackstone Life Sciences |
| Icosavax | Biotech & pharma | August 2019 | None on file |
| Amphivena Therapeutics | Biotech & pharma | December 2018 | MPM BioVentures |
| Platelet BioGenesis | Biotech & pharma | May 2017 | None on file |
| Aimmune Therapeutics | Biotech & pharma | November 2016 | Longitude Capital |
| Dermira | Biotech & pharma | August 2014 | Mustard Seed, Seedbrite Venture Partners, Techstars Corporate Partner, Techstars Ventures |
| FIVE PRIME THERAPEUTICS | Biotech & pharma | March 2014 | Versant Side |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Mark McDade on the board, based on 11 filed seats with a verified or cited source.